A new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.

Regeneron's trevogrumab trial has proved, overall, successful - potentially providing a solution to a reported Wegovy side ...

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Alexandria Real Estate offers a 7.5%+ yield and significant discounts to book value and equity versus peers. Read why ARE ...

HAYA Therapeutics Moves San Diego Operations to Lilly Gateway Labs® to Accelerate Development of RNA-Guided Therapeutics ...

New data indicates that American teenagers are increasingly using the weight-loss drug Wegovy, as confidence in its use for ...

US telehealth group explores selling ‘compounded medications’ in new markets after buying London-based rival Zava ...

Launched on 01/26/2004, the Vanguard Health Care ETF (VHT) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Broad segment of the equity market.

About 8 million American teens, or 23% of people ages 12 to 19, have obesity, up from 5% in 1980, according to U.S.

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...